Zacks Research Analysts Increase Earnings Estimates for IRWD

Key Points

• Zacks Research raised Ironwood Pharmaceuticals’ Q4 2027 EPS estimate to a loss of $0.02 per share from a previous forecasted loss of $0.03, while maintaining a “Hold” rating.
• Ironwood’s latest quarterly results slightly missed expectations, with EPS of $0.31 versus the $0.32 consensus and revenue of $113.04 million versus estimates of $114.84 million.
• The stock opened at $4.25 and has a “Moderate Buy” consensus rating, with analysts’ average price target at $6.23; institutional investors have recently increased or initiated positions, while two insiders sold shares.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities researchers at Zacks Research upped their Q4 2027 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a research report issued to clients and investors on Thursday, August 27th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings of ($0.02) per share for the quarter, up from their previous forecast of ($0.03). Zacks Research has a "Hold" rating on the stock. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $1.10 per share.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%.The company had revenue of $113.04 million for the quarter, compared to analyst estimates of $114.84 million.

A number of other equities research analysts also recently issued reports on the stock. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 22nd. Weiss Ratings upgraded shares of Ironwood Pharmaceuticals from a "hold (c-)" rating to a "hold (c+)" rating in a research report on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, Ironwood Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $6.23.

Ironwood Pharmaceuticals Stock Up 2.9%

IRWD stock opened at $4.25 on Tuesday. Ironwood Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $5.78. The business has a 50-day simple moving average of $4.15 and a 200 day simple moving average of $3.89. The company has a market cap of $702.27 million, a PE ratio of 5.52 and a beta of 0.20.

Institutional Trading of Ironwood Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. AXQ Capital LP grew its stake in shares of Ironwood Pharmaceuticals by 263.2% during the second quarter. AXQ Capital LP now owns 47,028 shares of the biotechnology company's stock worth $198,000 after buying an additional 34,079 shares during the last quarter. Wellington Management Group LLP increased its holdings in Ironwood Pharmaceuticals by 3.4% in the 2nd quarter. Wellington Management Group LLP now owns 468,821 shares of the biotechnology company's stock worth $1,974,000 after purchasing an additional 15,306 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in Ironwood Pharmaceuticals in the second quarter valued at about $252,000. Globeflex Capital L P bought a new position in Ironwood Pharmaceuticals in the second quarter valued at about $1,094,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Ironwood Pharmaceuticals in the second quarter valued at approximately $2,142,000.

Insider Transactions at Ironwood Pharmaceuticals

In other news, Director Julie Mchugh sold 21,571 shares of the firm's stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total value of $80,459.83. Following the sale, the director directly owned 250,749 shares in the company, valued at approximately $935,293.77. This trade represents a 7.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Ronald Silver sold 127,890 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total transaction of $578,062.80. Following the sale, the insider directly owned 313,680 shares in the company, valued at $1,417,833.60. This trade represents a 28.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 9.30% of the stock is currently owned by corporate insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company's flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source